- XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25
- Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the market
- The announcement comes as Germany reopens, meaning XPhyto is likely to benefit from a raft of regulatory requirements instituted by the government, which could potentially increase demand
- The Covid-ID Labs is both fast and accurate, factors that could make it the go-to product, given the inaccuracies and low sensitivity of many rapid antigen tests
As Germany reopens thanks to a drop in new COVID-19 infections, it has adopted a strategy that mandates anyone and everyone to prove they have been tested for the virus, have recently recovered from the disease, or have been fully vaccinated before entering any public space, including shops, outdoor dining areas, and, in some cases, indoor hospitality facilities (
https://ibn.fm/IOo17).
Earlier in March, the government made testing accessible to all at no cost, qualifying every resident to at least one free COVID-19 test per week, a policy whose implementation has continued since. As part of the…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at
https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the
InvestorBrandNetwork.